A certified cannabinoid ingredient manufacturer has completed a randomized, controlled trial on rare cannabinoids.
According to OBX, Radicle Science studied several of its formulations.
OBX says the four-week study utilized a randomized, controlled, parallel-group comparison to study the effects of different cannabinoid formulations on longer-term pain, well-being, and quality of life.
“We are excited to have partnered with OBX to conduct history’s largest randomized, controlled trial of cannabinoids pain, involving nearly 2,000 participants from across the U.S.,” says Radicle Science Co-Founder Dr. Jeff Chen. “This groundbreaking study also represents history’s first randomized controlled trial on the synergistic impact of rare cannabinoids like CBC and CBG on pain. A majority of all phytocannabinoid clinical research has centered around THC, and we are uncovering the untapped potential in the other phytocannabinoids found in the cannabis and hemp plant.”
OBX says it expects to have results from its study with Radicle Science in late April.
Additionally, OBX and Radicle Science plan to launch the first large-scale, blinded, randomized, placebo-controlled clinical trials on rare cannabinoids like tetrahydrocannabivarin (THCV), cannabinol (CBN), cannabigerol (CBG), and cannabichromene (CBC).
OBX says the study will examine the cannabinoids’ effects on energy, sleep, focus, appetite, stress, disturbance, and anxiety.
According to OBX, the study will involve more than 10,000 participants.
OBX’s CRO Dave Neundorfer says using scientifically-backed research to validate the therapeutic benefits of cannabinoids is a source of great pride for the company.
“We are on a quest to understand the true potential of cannabinoids and thank the Radicle Science team for providing a platform that supports the research that will help transform the CBD industry,” says Neundorfer. “The completion of this study is a key milestone in our research efforts and further demonstrates our commitment to scientific research and development for the cannabinoids industry as a whole.”